SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- Oncternal TherapeuticsInc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has deprioritized further development of ONCT-216 to reallocate resources to zilovertamab, the Companys investigational anti-ROR1 monoclonal antibody, and its Phase 3 registrational trial that the Company expects to initiate in Q3 2022. As such, the Company has discontinued enrollment in the Phase 1/2 study evaluating ONCT-216 in patients with relapsed or refractory Ewing sarcoma.
This asset prioritization allows us to further sharpen our focus on hematological malignancies and prostate cancer, while deploying our capital towards meaningful catalysts as we navigate this historically challenging pandemic, geopolitical and capital markets macroenvironment, said James Breitmeyer, MD, PhD, Oncternals President and CEO. We believe this focused approach, along with prudent cash management, will enable us to fund our operations well into the third quarter of 2023, as we continue to explore all potential sources of capital to enable us to reach our milestones.
The Company expects to initiate its global registrational Phase 3 Study ZILO-301 in the third quarter of 2022, taking into account the impact of geopolitical factors and COVID-19 related supply chain issues. The study will randomize patients with relapsed or refractory MCL who have experienced stable disease or a partial response after receiving four months of oral ibrutinib therapy to receive either blinded zilovertamab or placebo, and all patients will continue receiving oral ibrutinib. The novel ZILO-301 design is supported by encouraging data from the Companys ongoing Phase 1/2 clinical trial of zilovertamab plus ibrutinib for patients with MCL or CLL, as well as by a successful End-of-Phase-2 meeting with the U.S. Food and Drug Administration (FDA).
The Companys lead autologous ROR1-targeted CAR-T cell therapy program candidate, ONCT-808, is advancing according to plan towards an Investigational New Drug (IND) application submission expected in mid-2022, based on supportive manufacturing and preclinical data as well as a productive pre-IND meeting with the FDA earlier this year.
Finally, the Company continues to advance ONCT-534, its lead candidate in its DAARI program, and expects to initiate IND-enabling GLP toxicology studies and GMP manufacturing later this quarter. ONCT-534 has shown anti-tumor activity in preclinical studies relevant to multiple clinically important forms of resistance for patients with prostate cancer, including those involving overexpression of the androgen receptor, or expression of mutants of the androgen receptor, or splice variants such as AR-V7.
AboutZilovertamab (formerly Cirmtuzumab)Zilovertamab is an investigational, humanized, potentially first-in-class monoclonal antibody targeting Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab is currently being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with MCL or chronic lymphocytic leukemia (CLL), in a collaboration with theUniversity of California San Diego(UC San Diego) School of Medicine and theCalifornia Institute for Regenerative Medicine(CIRM). In addition, Oncternal is supporting two investigator-sponsored studies being conducted at the UC San Diego School of Medicine, a Phase 1b clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC), and a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, for patients with relapsed/refractory CLL. Both are open for enrollment.
ROR1 is a potentially attractive target for cancer therapy because it is an onco-embryonic antigen, not usually expressed on adult cells, but its expression confers a survival and fitness advantage when reactivated and expressed by tumor cells. Researchers at theUC San Diego School of Medicinediscovered that targeting a critical epitope on ROR1 was key to specifically inhibiting ROR1 expressing tumors. This led to the development of zilovertamab which binds this critical epitope of ROR1, highly expressed on many different cancers but not on normal tissues. Preclinical data showed that when zilovertamab bound to ROR1, it blocked Wnt5a signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of the tumor cells. The FDA has granted Orphan Drug Designations to zilovertamab for the treatment of patients with MCL and CLL/small lymphocytic lymphoma. Zilovertamab is in clinical development and has not been approved by the FDA for any indication.
About Oncternal TherapeuticsOncternal Therapeuticsis a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. The clinical pipeline includeszilovertamab, an investigational monoclonal antibody designed to inhibit ROR1, a type I tyrosine kinase-like orphan receptor. Zilovertamab is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), in investigator-initiated studies, including a Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, in a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL, and in a Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). Oncternal is also developingONCT-808, a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The early-stage pipeline also includesONCT-534, a dual-action androgen receptor inhibitor (DAARI), that is in preclinical development as a potential treatment for castration resistant prostate cancer and other androgen-receptor dependent diseases. More information is available athttps://oncternal.com/.
Forward-Looking Information
Oncternal cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as may, will, should, expect, plan, anticipate, could, intend, target, project, contemplates, believes, estimates, predicts, potential or continue or the negatives of these terms or other similar expressions. These statements are based on Oncternals current beliefs and expectations. Forward-looking statements include statements regarding Oncternals development programs, including Oncternals estimated cash and cash equivalents as of March 31, 2022, the anticipated timing for announcing additional preclinical and clinical data; timing of reaching any milestones, including IND submissions; timing for regulatory communications; Oncternals expected cash runway; and the potential that Study ZILO-301 can serve as a registrational clinical trial; and the expected initiation of clinical trials, including Study ZILO-301. Forward-looking statements are subject to risks and uncertainties inherent in Oncternals business, including risks associated with the clinical development and process for obtaining regulatory approval of Oncternals product candidates, such as potential delays in the commencement, enrollment and completion of clinical trials; we have not conducted head-to-head studies of zilovertamab in combination with ibrutinib compared to ibrutinib monotherapy and data from separate studies may not be directly comparable due to the differences in study protocols, conditions and patient populations; the risk that interim results of a clinical trial do not predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues, and as more patient data become available; later developments with the FDA may be inconsistent with the minutes from the completed end of Phase 2 meeting, including that the proposed Study ZILO-301 that may not support registration of zilovertamab in combination with ibrutinib which is a review issue with the FDA upon submission of a BLA; and other risks described in Oncternals filings with theU.S. Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Oncternal undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact Information:
InvestorsRichard Vincent858-434-1113rvincent@oncternal.com
MediaCorey Davis, Ph.D. LifeSci Advisors 212-915-2577 cdavis@lifesciadvisors.com
- More Stem Cells Extracted For Later Use For My MS [Last Updated On: March 14th, 2011] [Originally Added On: March 14th, 2011]
- Macular Degeneration Improved With Stem Cells [Last Updated On: April 2nd, 2011] [Originally Added On: April 2nd, 2011]
- Macular Degeneration Improved With Stem Cells [Last Updated On: April 3rd, 2011] [Originally Added On: April 3rd, 2011]
- Cells That Heal Us From Cradle To Grave: A Quantum Leap in Medical Science [Last Updated On: April 6th, 2011] [Originally Added On: April 6th, 2011]
- Stem Cell Patient Richard H. MS Treatment [Last Updated On: May 20th, 2011] [Originally Added On: May 20th, 2011]
- STEM CELLS FOR MACULAR DEGENERATION Sam Smith's story.wmv [Last Updated On: May 22nd, 2011] [Originally Added On: May 22nd, 2011]
- STEM CELLS FOR MACULAR DEGENERATION Sam Smith's story.wmv [Last Updated On: May 22nd, 2011] [Originally Added On: May 22nd, 2011]
- Dr. Janet Rossant, Premier's Summit Award 2010 recipient [Last Updated On: May 31st, 2011] [Originally Added On: May 31st, 2011]
- Visions Episode 92: Stem Cells Discovery [Last Updated On: May 31st, 2011] [Originally Added On: May 31st, 2011]
- PROSTATE CANCER and stem cells.wmv [Last Updated On: June 9th, 2011] [Originally Added On: June 9th, 2011]
- Stem Cells Used to Grow Windpipes [Last Updated On: June 10th, 2011] [Originally Added On: June 10th, 2011]
- Visions Episode 92: Stem Cells Discovery [Last Updated On: July 12th, 2011] [Originally Added On: July 12th, 2011]
- PROSTATE CANCER and stem cells [Last Updated On: July 16th, 2011] [Originally Added On: July 16th, 2011]
- Doctors Use Stem Cells to Grow New Windpipes [Last Updated On: August 29th, 2011] [Originally Added On: August 29th, 2011]
- Sims 2 Mafia Story Part 7 - Farewell, Godfather/Stem Cell Medicine [Last Updated On: August 30th, 2011] [Originally Added On: August 30th, 2011]
- Regenerative Medicine: Pathways to Cure - Version 2.0 [Last Updated On: September 8th, 2011] [Originally Added On: September 8th, 2011]
- Stem Cell Research: Huntington's Disease [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Adult Stem Cell Therapy for COPD: One Man's Story [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Stem Cell Update from Panama 3 Years Later [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Stem Cell Update from Panama 3 Years Later [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- Regenerative Medicine and Applications of Stem Cell Research [Last Updated On: October 10th, 2011] [Originally Added On: October 10th, 2011]
- Stem Cell Therapy for Sickle Cell Anemia - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Stem_Cell_Therapy_for_ALS.wmv - Video [Last Updated On: October 17th, 2011] [Originally Added On: October 17th, 2011]
- Spinal Cord Injury: Progress and Promise in Stem Cell Research - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- Stem Cells: The Hope The Hype and the Science - Video [Last Updated On: October 22nd, 2011] [Originally Added On: October 22nd, 2011]
- What are stem cells? How can they be used for medical benefit? - Video [Last Updated On: October 24th, 2011] [Originally Added On: October 24th, 2011]
- What are stem cells? How can they be used for medical benefit? - Video [Last Updated On: October 25th, 2011] [Originally Added On: October 25th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - Stephen Huhn - Video [Last Updated On: October 26th, 2011] [Originally Added On: October 26th, 2011]
- The CIRM Creativity Awards: Training 21st Century Stem Cell Scientists - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- What Organ Shortage? Just Make Your Own! Stem Cells and Organ Engineering - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- StemEnhance is the Biggest Scientific Medical breakthrough of our time - World Exclusive! - Video [Last Updated On: November 9th, 2011] [Originally Added On: November 9th, 2011]
- StemEnhance is the Biggest Scientific Medical breakthrough of our time - World Exclusive! - Video [Last Updated On: November 10th, 2011] [Originally Added On: November 10th, 2011]
- Alumni Profile: Dr. John Tisdale, NIH Researcher, Stem Cell Transplants and Sickle Cell - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- Intel co-founder Andrew Grove gives keynote at 2011 World Stem Cell Summit in Pasadena - Video [Last Updated On: November 16th, 2011] [Originally Added On: November 16th, 2011]
- Austin Forum - Nov 1st (Highlights) - Video [Last Updated On: November 17th, 2011] [Originally Added On: November 17th, 2011]
- Stem Cell Based Therapies for Blindness: David Hinton - CIRM Science Writer's Seminar - Video [Last Updated On: November 18th, 2011] [Originally Added On: November 18th, 2011]
- Dr. Jordan Pomeroy discusses xeno-Free Derivation and Maintenance of Pluripotent Cell Lines - Video [Last Updated On: November 19th, 2011] [Originally Added On: November 19th, 2011]
- So Many Chemicals...So Little Time: Stem Cell Research and Environmental Health - Video [Last Updated On: November 19th, 2011] [Originally Added On: November 19th, 2011]
- Austin Forum - Nov 1st (Part 4 of 4) - Video [Last Updated On: November 23rd, 2011] [Originally Added On: November 23rd, 2011]
- Austin Forum - Nov 1st (Part 2 of 4) - Video [Last Updated On: November 23rd, 2011] [Originally Added On: November 23rd, 2011]
- Austin Forum - Nov 1st (Part 1 of 4) - Video [Last Updated On: November 24th, 2011] [Originally Added On: November 24th, 2011]
- Alan Trounson: Are stem cells the end of disease? - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- Alan Trounson: Are stem cells the end of disease? - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- A4M Stem Cell Fellowship Module II Preview - Video [Last Updated On: December 1st, 2011] [Originally Added On: December 1st, 2011]
- Auxogyn_ASRM_FINAL.mov - Video [Last Updated On: December 2nd, 2011] [Originally Added On: December 2nd, 2011]
- Bruce Lipton,making the connections part 1 - Video [Last Updated On: December 3rd, 2011] [Originally Added On: December 3rd, 2011]
- Assessment of Embryo Viability (Auxogyn_ASRM_First Prize) - Video [Last Updated On: December 4th, 2011] [Originally Added On: December 4th, 2011]
- What is Cord Blood Banking? The Medical Potential of Newborn Stem Cells - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- NAMCP 2011: Ravi Vij, MD, Associate Professor of Medicine, Washington University School of Medicine - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- StemCellTV Talks to Michael Werner of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- Future360 - Alan Trounson, CEO of the California Institute of Regenerative Medicine - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- 2011 World Stem Cell Summit Open Comments [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 2011 Summit: Keynote Address, CIRM's Translational Roadmap to Stem Cell Cures, Alan Trounson, PhD - Video [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- 2011 Summit: Government [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- Autism Stem Cell Trip - Video [Last Updated On: December 17th, 2011] [Originally Added On: December 17th, 2011]
- GeneCell International Dental Pulp Stem Cell's Banking Services - Video [Last Updated On: December 21st, 2011] [Originally Added On: December 21st, 2011]
- GeneCell International Dental Pulp Stem Cell's Banking Services - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]
- Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan - Video [Last Updated On: January 2nd, 2012] [Originally Added On: January 2nd, 2012]
- Craig Venter: Understanding Our Genes - A Step to Personalized Medicine | CIRM Spotlight on Genomics - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- Craig Venter: Understanding Our Genes - A Step to Personalized Medicine | CIRM Spotlight on Genomics - Video [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- Aesthetic Plastic Surgery / Anti Aging Medicine: The Next Generation Symposium Attracts a World Class Faculty to New ... [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- Lecture by stem cell researcher tomorrow [Last Updated On: January 29th, 2012] [Originally Added On: January 29th, 2012]
- Biobanking for Medicine: Technology and Market 2012-2022 [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- 'Personalized medicine' gets $67.5M research boost [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Clinical Trial for Myelofibrosis that Targets Cancer Stem Cells | CIRM Spotlight on Genomics - Video [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use - James P. Watson, MD - Video [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use - James P. Watson, MD - Video [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- Dr. Ramaswamy on Targeting Dormant Cancer Cells - Video [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- Daniel Kraft on Singularity 1 on 1 (part 3) - Video [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- Daniel Kraft on Singularity 1 on 1 (part 1) - Video [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- Statement - Rx&D Applauds Government of Canada for Investing in Personalized Medicine [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- Molecules to Medicine: Plan B: The Tradition of Politics at the FDA [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- 'Personalized medicine' gets $67.5M research boost [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- The Pet Corner: Behold! The future of modern medicine is here [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- Molecules to Medicine: Plan B: The Tradition of Politics at the FDA [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- Treating Brain Injuries With Stem Cell Transplants - Promising Results [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- Stem Cells to Treat Acne Scarring | Los Angeles | Hollywood | Beverly Hills - Video [Last Updated On: February 6th, 2012] [Originally Added On: February 6th, 2012]
- American CryoStem Completes Cell Processing for Clinical Study [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- IntelliCell Demonstrates at the American Sports Medicine Institute Held in Conjunction with and at the Andrews Sports ... [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- Meet the Founders of Cord Blood Registry - Video [Last Updated On: February 9th, 2012] [Originally Added On: February 9th, 2012]